Literature DB >> 18826359

Neuroprotective effects of erythropoietin on acute metabolic and pathological changes in experimentally induced neurotrauma.

Chad E Hartley1, Madhu Varma, John P Fischer, Richard Riccardi, Judith A Strauss, Sejal Shah, Shengle Zhang, Zhong-Jin Yang.   

Abstract

OBJECT: Head trauma is a dynamic process characterized by a cascade of metabolic and molecular events. Erythropoietin (EPO) has been shown to have neuroprotective effects in animal models of traumatic brain injury (TBI). Acute in vivo mechanisms and pathological changes associated with EPO following TBI are unknown. In this study the authors compare acute metabolic and pathological changes following TBI with and without systemically administered EPO.
METHODS: Right frontal lobe microdialysis cannulae and right parietal lobe percussion hubs were inserted into 16 Sprague-Dawley rats. After a 4- to 5-day recovery, TBI was induced via a DragonFly fluid-percussion device at 2.5-2.8 atm. Rats were randomized into 2 groups, which received 5000 U/kg EPO or normal saline intraperitoneally 30 minutes after TBI. Microdialysis samples for glucose, lactate, pyruvate, and glutamate were obtained every 25 minutes for 10 hours. Rats were killed, their brains processed for light microscopy, and sections stained with H & E.
RESULTS: Erythropoietin administered 30 minutes after TBI directly affects acute brain metabolism. Brains treated with EPO maintain higher levels of glucose 4-10 hours after TBI (p<0.01), lower levels of lactate 6-10 hours after TBI (p<0.01), and lower levels of pyruvate 7.5-10 hours after TBI (p<0.01) compared with saline-treated controls. Erythropoietin maintains aerobic metabolism after TBI. Systemic EPO administration reduces acute TBI-induced lesion volume (p<0.05).
CONCLUSIONS: Following TBI, neuron use initially increases, with subsequent depletion of extracellular glucose, resulting in increased levels of extracellular lactate and pyruvate. This energy requirement can result in cell death due to increased metabolic demands. These data suggest that the neuroprotective effect of EPO may be partially due to improved energy metabolism in the acute phase in this rat model of TBI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18826359     DOI: 10.3171/JNS/2008/109/10/0708

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  10 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  White matter changes in patients with friedreich ataxia after treatment with erythropoietin.

Authors:  Karl Egger; Christian Clemm von Hohenberg; Michael F Schocke; Charles R G Guttmann; Demian Wassermann; Marlene C Wigand; Wolfgang Nachbauer; Christian Kremser; Brigitte Sturm; Barbara Scheiber-Mojdehkar; Marek Kubicki; Martha E Shenton; Sylvia Boesch
Journal:  J Neuroimaging       Date:  2013-09-09       Impact factor: 2.486

3.  Treatment of traumatic brain injury with thymosin β₄ in rats.

Authors:  Ye Xiong; Asim Mahmood; Yuling Meng; Yanlu Zhang; Zheng Gang Zhang; Daniel C Morris; Michael Chopp
Journal:  J Neurosurg       Date:  2010-05-21       Impact factor: 5.115

4.  Erythropoietin promotes neurovascular remodeling and long-term functional recovery in rats following traumatic brain injury.

Authors:  Ruizhuo Ning; Ye Xiong; Asim Mahmood; Yanlu Zhang; Yuling Meng; Changsheng Qu; Michael Chopp
Journal:  Brain Res       Date:  2011-02-03       Impact factor: 3.252

5.  Neurometabolite concentrations in gray and white matter in mild traumatic brain injury: an 1H-magnetic resonance spectroscopy study.

Authors:  Charles Gasparovic; Ronald Yeo; Maggie Mannell; Josef Ling; Robert Elgie; John Phillips; David Doezema; Andrew R Mayer
Journal:  J Neurotrauma       Date:  2009-10       Impact factor: 5.269

6.  Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neural erythropoietin receptor.

Authors:  Ye Xiong; Asim Mahmood; Changsheng Qu; Humaira Kazmi; Zheng Gang Zhang; Constance T Noguchi; Timothy Schallert; Michael Chopp
Journal:  J Neurotrauma       Date:  2010-01       Impact factor: 5.269

Review 7.  Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.

Authors:  Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer
Journal:  J Neurotrauma       Date:  2014-01-15       Impact factor: 5.269

8.  Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose.

Authors:  Ye Xiong; Asim Mahmood; Yuling Meng; Yanlu Zhang; Changsheng Qu; Timothy Schallert; Michael Chopp
Journal:  J Neurosurg       Date:  2010-09       Impact factor: 5.115

9.  Effects of Quercetin and Mannitol on Erythropoietin Levels in Rats Following Acute Severe Traumatic Brain Injury.

Authors:  Orhan Kalemci; Hasan Emre Aydin; Ceren Kizmazoglu; Ismail Kaya; Hulya Yılmaz; Nuri M Arda
Journal:  J Korean Neurosurg Soc       Date:  2017-05-01

10.  Experimental studies of erythropoietin protection following traumatic brain injury in rats.

Authors:  Feng Xu; Zheng-Yuan Yu; Li Ding; Shi-Ying Zheng
Journal:  Exp Ther Med       Date:  2012-09-25       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.